The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome
| Autor: | Dirk Hendriks, D. de Surgeloose, Rishi Sheorajpanday, Raf Brouns, J. L. Willemse, P.P. De Deyn, Evelien Heylen, Robert Verkerk |
|---|---|
| Přispěvatelé: | Internal Medicine Specializations |
| Rok vydání: | 2010 |
| Předmět: |
Male
TAFI Carboxypeptidase B2 medicine.medical_specialty Time Factors Stroke severity Down-Regulation stroke outcome stroke evolution Stroke evolution Risk Assessment Severity of Illness Index Brain Ischemia Disability Evaluation Predictive Value of Tests Risk Factors Internal medicine Stroke outcome medicine Humans In patient cardiovascular diseases procarboxypeptidase U Stroke Acute ischemic stroke Aged Aged 80 and over Procarboxypeptidase U business.industry Acute cerebral infarction stroke severity Reproducibility of Results Hematology Middle Aged medicine.disease Logistic Models Treatment Outcome Infarct volume Physical therapy Cardiology Female Human medicine business Biomarkers |
| Zdroj: | Vrije Universiteit Brussel Journal of thrombosis and haemostasis |
| ISSN: | 1538-7836 1538-7933 |
| DOI: | 10.1111/j.1538-7836.2009.03663.x |
| Popis: | See also Willemse JL, Brouns R, Heylen E, De Deyn PP, Hendriks DF. Carboxypeptidase U (TAFIa) activity is induced in vivo in ischemic stroke patients receiving thrombolytic therapy. J Thromb Haemost 2008; 6: 200–2. Summary. Background and objectives: Procarboxypeptidase U (proCPU, TAFI) concentration in plasma is potentially related to thrombotic tendency, and elevated proCPU levels have been reported in ischemic stroke patients. Improved insight into the role of proCPU in acute ischemic stroke is essential for the development of more adequate therapeutics that may include carboxypeptidase inhibitors. In this study we investigated whether the plasma concentration of proCPU and the proCPU kinetic profile in acute ischemic stroke are related to initial stroke severity, stroke evolution in the subacute phase and long-term stroke outcome. Methods: Plasma concentration of proCPU was assessed in 136 stroke patients at admission (7.5 h after stroke onset), at 24 h, at 72 h and at day 7 after stroke onset. We evaluated the relation between change in proCPU concentrations and (a) stroke severity (patients with TIA vs. stroke patients, NIHSS score at admission), (b) stroke evolution (stroke progression, infarct volume at 72 h), and (c) stroke outcome (mRS score at month 3). Results: ProCPU concentration decreased significantly in the first 72 h after stroke onset and thereafter returned to baseline. This biphasic time course, with its nadir at 72 h, was more pronounced in patients with severe stroke, unfavourable stroke evolution in the first 72 h and poor long-term outcome. Conclusions: The decrease in proCPU concentration in the first 72 h after stroke onset correlates with more severe stroke, unfavourable stroke evolution, and poor long-term stroke outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text